Robert Z. Orlowski

53.0k total citations · 6 hit papers
514 papers, 18.6k citations indexed

About

Robert Z. Orlowski is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert Z. Orlowski has authored 514 papers receiving a total of 18.6k indexed citations (citations by other indexed papers that have themselves been cited), including 414 papers in Hematology, 333 papers in Molecular Biology and 214 papers in Oncology. Recurrent topics in Robert Z. Orlowski's work include Multiple Myeloma Research and Treatments (402 papers), Protein Degradation and Inhibitors (197 papers) and Ubiquitin and proteasome pathways (115 papers). Robert Z. Orlowski is often cited by papers focused on Multiple Myeloma Research and Treatments (402 papers), Protein Degradation and Inhibitors (197 papers) and Ubiquitin and proteasome pathways (115 papers). Robert Z. Orlowski collaborates with scholars based in United States, Canada and Spain. Robert Z. Orlowski's co-authors include Deborah J. Kuhn, Elisabet E. Manasanch, Peter M. Voorhees, Albert S. Baldwin, Jatin J. Shah, George W. Small, Paul G. Richardson, Elizabeth Claire Dees, Sundar Jagannath and Yue Shi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Robert Z. Orlowski

491 papers receiving 18.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors in cancer therapy

2017 699 citations Elisabet E. Manasanch, Robert Z. Orlowski profile →
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

2016 594 citations Robert Z. Orlowski et al. profile →
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

2007 591 citations Deborah J. Kuhn, Qing Chen et al. profile →
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 586 citations Robert Z. Orlowski, Owen A. O’Connor et al. Journal of Clinical Oncology profile →
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

2007 505 citations Robert Z. Orlowski et al. Journal of Clinical Oncology profile →
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

2011 461 citations Chad C. Bjorklund, Robert Z. Orlowski et al. profile →

Peers

Countries citing papers authored by Robert Z. Orlowski

Since Specialization

Citations

This map shows the geographic impact of Robert Z. Orlowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Z. Orlowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Z. Orlowski more than expected).

Fields of papers citing papers by Robert Z. Orlowski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Z. Orlowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Z. Orlowski. The network helps show where Robert Z. Orlowski may publish in the future.

Co-authorship network of co-authors of Robert Z. Orlowski

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Z. Orlowski. A scholar is included among the top collaborators of Robert Z. Orlowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Z. Orlowski. Robert Z. Orlowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis 2024 ·Nature Communications ·Miao Xian, Qiang Wang, Liuling Xiao, (unknown), Wei Xiong, Lingqun Ye, Su Pan, Chuanchao Zhang, (unknown), Robert Z. Orlowski, (unknown), Siddhartha Ganguly, Youli Zu, Jianfei Qian, Qing Yi	15
2	Exploring gender-based decision-making differences among patients with relapsed/refractory multiple myeloma. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Robert Z. Orlowski, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jay R. Hydren	1
3	Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma 2023 ·npj Precision Oncology ·(unknown), (unknown), (unknown), Valerie Hennes, (unknown), Guilin Tang, Pei Lin, Robert Z. Orlowski, David E. Symer, Elisabet E. Manasanch, Stephanie N. Shishido, Peter Kühn	8
4	Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation 2023 ·Cancer ·Oren Pasvolsky, (unknown), Roland L. Bassett, Hina Khan, Mark R. Tanner, Qaiser Bashir, Samer A. Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash	1
5	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma 2022 ·Clinical Cancer Research ·Krina K. Patel, Jatin J. Shah, (unknown), Hans C. Lee, (unknown), (unknown), (unknown), (unknown), Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski	7
6	Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma 2022 ·Transplantation and Cellular Therapy ·(unknown), Muzaffar H. Qazilbash, Penny Fang, Susan Wu, Bouthaina S. Dabaja, Gabriela Rondón, Chitra Hosing, Richard E. Champlin, Qaiser Bashir, Elizabeth J. Shpall, Mark Knafl, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Donna M. Weber, Chelsea C. Pinnix, Jillian R. Gunther	2
7	Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Stephanie N. Shishido, (unknown), Guilin Tang, Pei Lin, (unknown), (unknown), (unknown), Carmen Ruiz Velasco, (unknown), (unknown), Kevin R. Kelly, James Hicks, Jeremy Mason, Robert Z. Orlowski, (unknown), Peter Kühn	5
8	Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Behrang Amini, Samer A. Srour, Qaiser Bashir, Yago Nieto, (unknown), Donna M. Weber, Lei Feng, Robert Z. Orlowski, Pei Lin, Elisabet E. Manasanch	9
9	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191 2018 ·Clinical Cancer Research ·(unknown), Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuiatse, Hua Wang, Richard J. Jones, Zuzana Berkova, Yasumichi Hitoshi, Stephen M. Ansell, Steven P. Treon, Sheeba K. Thomas, Hans C. Lee, Zhiqiang Wang, R. Eric Davis, Robert Z. Orlowski	14
10	Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein–Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression 2016 ·Clinical Cancer Research ·Richard J. Jones, Tawin Iempridee, Xiaobin Wang, Hans C. Lee, Janet E. Mertz, Shannon C. Kenney, (unknown), Veerabhadran Baladandayuthapani, William O. Dawson, Jatin J. Shah, Donna M. Weber, Robert Z. Orlowski	39
11	Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma 2015 ·Clinical Cancer Research ·Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Robert Z. Orlowski, R. Donald Harvey, Mitchell R. Smith, Daniel Lebovic, Catherine Diefenbach, Kevin R. Kelly, Zhaowei Hua, Allison Berger, George Mulligan, Hélène M. Faessel, Stephen Tirrell, Bruce J. Dezube, Sagar Lonial	162
12	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia 2015 ·Clinical Cancer Research ·Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing‐Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski	16
13	Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses 2014 ·Clinical Cancer Research ·Kathleen Coughlin, Ravi Anchoori, Yoshie Iizuka, (unknown), (unknown), Rachel I. Vogel, Robert Z. Orlowski, Michael K. Lee, Richard B.S. Roden, Martina Bazzaro	57
14	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies 2012 ·Cancer Research ·Shuang Chen, Yun Dai, (unknown), (unknown), Li Wang, Lora B. Kramer, (unknown), Daniella M. Schwartz, (unknown), Gary Simmons, (unknown), (unknown), Paul Dent, Robert Z. Orlowski, Steven Grant	46
15	p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction 2012 ·Cancer Research ·Jin He, Zhiqiang Liu, Yuhuan Zheng, Jianfei Qian, Haiyan Li, Yong Lu, Jingda Xu, Bangxing Hong, Mingjun Zhang, Pei Lin, Zhen Cai, Robert Z. Orlowski, Larry W. Kwak, Qing Yi, Jing Yang	69
16	Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA 2012 ·Molecular Cancer Therapeutics ·Richard J. Jones, Chad C. Bjorklund, Veerabhadran Baladandayuthapani, Deborah J. Kuhn, Robert Z. Orlowski	46
17	Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Wencai Ma, Michael Wang, Zhiqiang Wang, Luhong Sun, (unknown), Jairo Matthews, Richard Champlin, Qing Yi, Robert Z. Orlowski, Larry W. Kwak, Donna M. Weber, Sheeba K. Thomas, Jatin J. Shah, Steven M. Kornblau, R. Eric Davis	35
18	Inhibition of the p53 E3 Ligase HDM-2 Induces Apoptosis and DNA Damage–Independent p53 Phosphorylation in Mantle Cell Lymphoma 2008 ·Clinical Cancer Research ·Richard J. Jones, Qing Chen, Peter M. Voorhees, Ken H. Young, Nathalie Bruey-Sédano, Dajun Yang, Robert Z. Orlowski	27
19	Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma 2007 ·Clinical Cancer Research ·Peter M. Voorhees, Qing Chen, Deborah J. Kuhn, George W. Small, Sally A. Hunsucker, John S. Strader, Robert Corringham, Mohamed H. Zaki, Jeffrey A. Nemeth, Robert Z. Orlowski	93
20	Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance 2007 ·Cancer Research ·George W. Small, Yue Shi, Linda S. Higgins, Robert Z. Orlowski	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact